15 May 2020

Oncode Institute is in Top 50 NPO/NGOs ranked by Nature Index

Bianca-Olivia Nita

We are honoured to announce that Nature Index included Oncode Institute in its Top 50 NPO/NGO institutions in cancer research worldwide.

Every year, Nature Index publishes its Cancer supplement, featuring a list of the most prominent institutes and academic, healthcare, NPO/NGO, government and corporate institutions working in cancer research. The ranking is made according to each organization’s impact in terms of article share in a selective list of top journals over a period of 4.5 years. This year’s ranking has been made by looking at the period between January 2015 and August 2019.

Geert Kops, Scientific Director of Oncode Institute, says: “We are very proud that Oncode is mentioned on this list, since we are quite a young institute. The data was taken from 2015 onwards, therefore it will be interesting to see how our ranking will be impacted in the coming years. Congratulations to all our Oncode researchers for contributing to this achievement!”

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.